Innovation Beverage Group Limited

Sources: FY2025 and restated FY2024 from the FY2025 Form 20-F (filed 17 Sep 2026) and the Quartr summary of it. FY2021–FY2023 (and originally reported FY2024) from S&P Global Market Intelligence via StockAnalysis.com, which derives them from the F-1 and FY2024 20-F. All figures are USD millions unless stated.

Income statement

Notes: FY2021–FY2023 pre-tax income is derived from S&P pre-tax margin × revenue. FY2024 is shown restated (FY2025 20-F). As originally reported, FY2024 revenue was 2.93, operating income −2.58 and net income −2.57 (S&P/StockAnalysis). FY2024 tax benefit and FY2025 tax expense are derived as net loss minus pre-tax loss.

Margins and growth

Notes: FY2024 and FY2025 operating and net margins are computed on restated 20-F figures. As originally reported, FY2024 operating margin was −88.2% and net margin −87.7% (S&P). Revenue growth for FY2024 on restated revenue is −7.2%; −6.9% as originally reported. FY2025 growth is −5.1% (Quartr/20-F).

Revenue CAGR FY2021–FY2025: about −7.3% per year (US$3.75M to US$2.77M). Since the FY2022 peak the decline is about −15.1% per year (US$4.53M to US$2.77M).

Balance sheet

Sources: S&P/StockAnalysis for cash and debt in FY2021–FY2024. FY2025 cash (US$128K) and working-capital deficit (US$2.0M) from the FY2025 20-F via Quartr. FY2025 equity of −US$1,469,914 from the FY2025 20-F as cited in the 25 Sep 2026 PR. The short-term/long-term debt split is n/d. Intangible assets (customer contracts, software development costs, a liquor licence, contract services) are described as significant in the 20-F risk factors, but carrying values are n/d. The 20-F states that a separately described impairment-related balance was zero at end-FY2024 and FY2025.

Post-period: an unaudited balance sheet at 31 Mar 2026 shows stockholders' equity of US$5,003,707, excluding BlockFuel consolidation. The improvement reflects the March 2026 US$6M offering and related transactions (PR 25 Sep 2026). S&P shows cash of US$0.19M and debt of US$0.72M at 30 Jun 2025.

Cash flow

Sources: S&P/StockAnalysis for FY2021–FY2024. Benzinga shows TTM operating cash flow of about −US$1.56M (period unclear). FY2025 cash-flow statement line items n/d.

Ratios

Commentary: With negative equity at FY2025 and negative EBIT and EBITDA in every year since FY2022, return and leverage ratios are either negative or not meaningful. ROE cannot be computed on negative equity. Interest coverage is negative.

Commentary on trends, inflections and drivers

Revenue. The business peaked in FY2022 at US$4.53M, when U.S. sales (US$1.95M) briefly made up about 43% of revenue. U.S. revenue then collapsed to US$0.27M in FY2023 and roughly zero in FY2024. That decline explains essentially all of the group's contraction. The Australian base, which is essentially CCEP bitters supply, has been stable at about US$2.6–2.9M. FY2024 revenue fell because of lower bitters sales to CCEP and other overseas customers and lower DTC marketplace sales (FY2024 20-F summary). FY2025 fell a further 5.1% mainly because a CCEP order cycle was missed, leaving only 11 months of recognised sales (FY2025 20-F via Quartr). This shows the fragility of a one-customer revenue line: a single missed order cycle moved the top line by about 5%.

Gross margin. Margin rose from 53% (FY2022) to 76% (FY2024) as the mix shifted toward high-margin CCEP bitters and away from lower-margin U.S. branded sales. FY2025's fall to 44.2% reflects higher raw-material costs and a roughly US$330K inventory write-down. Without the write-down, FY2025 gross margin would have been about 56%, still well below FY2024.

Operating costs. Restated operating expenses of US$7.29M in FY2024 and US$6.61M in FY2025 are 2.4–2.5x revenue. They include listing costs, contracted services, consultancy, advertising and new-product development. The 9.3% opex reduction in FY2025 was more than offset by the gross-profit decline.

Net loss. The FY2025 net loss of US$6.19M was 31.8% worse than FY2024 (restated).

Liquidity. Cash of US$128K and a US$2.0M working-capital deficit at end-2025 led to going-concern doubt (FY2025 20-F). The March 2026 offering (US$6M gross, of which US$2.5M was lent to BlockFuel) and about US$2M raised under an ATM programme by the 20-F date provided temporary relief.

Restatement. The FY2024 restatement roughly doubled the reported operating loss and increased the net loss by about US$2.1M. It was attributed to control weaknesses in GAAP application, segregation of duties, and related-party identification. This materially lowers confidence in the historical numbers.

Management guidance and consensus

Management guidance: no quantitative guidance. Stated priorities are revenue growth, cost control, financing, U.S./U.K. bitters expansion and completion of the BlockFuel merger (FY2025 20-F; PRs 2026).

Consensus: none meaningful (no active coverage).

Bull case

1. Merger-driven re-rating. If the merger closes, IBG holders keep 10% of an entity independently valued at US$220M–343M (Marshall & Stevens, Oct 2025). That implies US$22M–34M against today's US$2–4M market cap.

2. Tangible upstream progress. BlockFuel has returned 19 wells to production (about 100 bopd cited), completed an independent reserve report, expanded to 61 operated wells, and laid out an 8-well 2026 drilling programme. This is operating evidence rather than a concept.

3. Embedded, cash-generative niche. The CCEP bitters line ran at a 76% gross margin in FY2024. A beverage subsidiary relieved of public-company costs (opex US$6.6M) could approach break-even, and the plant has tenfold spare capacity.

Bear case

1. Going concern and listing. FY2025 equity was −US$1.47M and year-end cash US$128K, against three Nasdaq notices in nine months and a sub-US$1 price after a 1:25 consolidation. Delisting before merger completion is a live risk.

2. Concentration combined with change-of-control. About 94% of revenue depends on CCEP, which can terminate on a change of control. The merger could jeopardise the one asset generating revenue.

3. Execution, governance and dilution. Repeated slippage in merger timing, a restatement, material weaknesses (including related-party controls), conflicted board representation, and heavy warrant and ATM dilution all point to continued value transfer away from existing holders.

Key catalysts and monitorables (next 12 months)

Analyst verdict

Innovation Beverage Group is no longer primarily a beverage investment. Its listed equity has become a reverse-merger vehicle for BlockFuel Energy, and the beverage operations are a small and deteriorating appendage. On standalone fundamentals the picture is unambiguous. Revenue has shrunk at about 7% a year since FY2021 to US$2.77M. Gross margin collapsed from 76% to 44% in a single year. Opex runs at about 2.4x sales, and the FY2025 net loss of US$6.19M exceeded twice revenue. Year-end equity was negative and cash was US$128K. The auditor raised substantial going-concern doubt, and the prior year's accounts had to be restated because of control failures. A single customer contract with CCEP supplies about 94% of revenue, and that contract can be terminated on a change of control, which is exactly what the merger would deliver.

The investment case therefore rests almost entirely on BlockFuel. There is real, if early, evidence there: reactivated wells, an independent reserve report, bolt-on acquisitions and a funded first drilling programme. The fairness-opinion valuation, however, sits an order of magnitude above where the market prices the shares, and the market has repeatedly discounted the deal through delayed closing dates, dilutive financings and a roughly 99% split-adjusted decline since the IPO. The 51% interest acquired in March 2026 was not consolidated in the reported interim balance sheet, which limits visibility into what IBG shareholders currently own economically.

Verdict: IBG is a highly speculative, binary special situation. Downside scenarios (delisting, CCEP termination, further dilution, merger failure) have a high probability and could wipe out remaining equity value. The upside depends on a timely merger close and on BlockFuel's production translating into cash flow. Only investors able to diligence BlockFuel's reserves and capital needs directly should engage. On the evidence available, risk-adjusted value appears unattractive, and the key monitorables are Nasdaq compliance and the merger timetable over the next two quarters.